Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FORGOTTEN HISTORY: Viatris recalls one batch of diabetes treatment semglee citing missing label risks - Caught on Camera

Viatris Inc's (NASDAQ:VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection. 

  • The Company cited the risk of the label is missing on some prefilled pens contained inside labeled cartons of the drug.
  • The recall doesn't cover Viatris' recently launched interchangeable Semglee biosimilars, which come in branded and unbranded formats.
  • The lot in question was produced by Biocon and distributed by Mylan in the U.S. between May 11, 2021, and Nov. 11, 2021. 
  • According to the release, the batch, which contains cartons of five 3-ml prefilled Semglee pens, was due to expire in August 2022.
  • Viatris did not say how many five-pen cartons were in the lot. 
  • The labeling glitch could pose problems for patients who use both long- and short-acting insulin to manage their diabetes, Viatris warned. 
  • Patients could accidentally take the wrong insulin, which could hamper glycemic control, resulting in serious health risks.
  • As of Wednesday, Viatris had not received any safety reports linked to the recall.
  • Price Action: VTRS shares are up 0.28% at $14.76 during the market session on the last check Thursday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.